IMDX
Insight Molecular Diagnostics Inc.
Price Chart
Latest Quote
$5.59
+0.21 (+3.90%)
Current Price
| Previous Close | $5.38 |
| Open | $5.47 |
| Day High | $5.69 |
| Day Low | $5.47 |
| Volume | 27,847 |
Stock Information
| Shares Outstanding | 32.29M |
| Total Debt | $3.07M |
| Cash Equivalents | $28.20M |
| Revenue | $1.95M |
| Net Income | $-47.84M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $180.50M |
| EPS (TTM) | $-1.51 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $148.59M |
| Sales | $1.95M |
| Income | $-47.84M |
| Book/sh | $-0.33 |
| Cash/sh | $0.87 |
| Employees | 55 |
Financial Ratios
| Quick Ratio | 2.36 |
| Current Ratio | 2.54 |
Returns & Margins
| ROA | -43.39% |
| Gross Margin | 51.05% |
| Operating Margin | -32275.00% |
Ownership
| Insider Ownership | 20.45% |
| Institutional Ownership | 61.45% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -7.17 |
| P/S | 92.61 |
| P/B | -16.89 |
Analyst Data
| Recommendation | none |
| Target Price | $8.33 |
Technical Indicators
| SMA20 | $5.73 |
| SMA50 | $5.19 |
| SMA200 | $5.28 |
| RSI | 35.88 |
| ATR | 0.6243 |
| Shares Float | 9.97M |
| Short Float | 8.08% |
| Short Ratio | 2.84 |
| Volatility | 1.77 |
| Rel Volume | 0.10 |
Performance History
| Week | +5.08% |
| Month | -13.20% |
| Quarter | +35.02% |
| 6 Months | +0.54% |
| YTD | -21.93% |
| Year | +62.03% |
| 3 Years | +30.00% |
| 5 Years | -95.04% |
| 10 Years | -91.71% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $5.59 | 27,847 |
| 2026-06-24 | $5.38 | 313,400 |
| 2026-06-23 | $5.37 | 119,800 |
| 2026-06-22 | $5.40 | 240,400 |
| 2026-06-18 | $5.44 | 694,700 |
| 2026-06-17 | $5.32 | 281,900 |
| 2026-06-16 | $5.32 | 276,700 |
| 2026-06-15 | $5.70 | 231,600 |
| 2026-06-12 | $5.61 | 389,900 |
| 2026-06-11 | $5.43 | 277,800 |
| 2026-06-10 | $5.76 | 196,900 |
| 2026-06-09 | $5.85 | 138,100 |
| 2026-06-08 | $5.72 | 466,500 |
| 2026-06-05 | $5.24 | 292,200 |
| 2026-06-04 | $6.55 | 447,100 |
| 2026-06-03 | $6.03 | 240,100 |
| 2026-06-02 | $5.95 | 203,200 |
| 2026-06-01 | $6.16 | 95,100 |
| 2026-05-29 | $6.21 | 238,200 |
| 2026-05-28 | $6.53 | 151,500 |
| 2026-05-27 | $6.41 | 470,600 |
| 2026-05-26 | $6.44 | 273,800 |
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
đ° Latest News
âBreakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)âs Defining Moment
Insider Monkey âĸ 2026-06-19T18:17:14Z
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission
Simply Wall St. âĸ 2026-05-15T13:16:04Z
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call Highlights: Strategic Advances ...
GuruFocus.com âĸ 2026-05-14T05:00:56ZHow The Insight Molecular Diagnostics (IMDX) Story Is Shifting With Funding And GraftAssureDx Milestones
Simply Wall St. âĸ 2026-04-29T00:18:27Z
Why The Insight Molecular Diagnostics (IMDX) Story Is Shifting After Cash Raise And FDA Catalyst
Simply Wall St. âĸ 2026-04-13T22:08:49Z
How The Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And FDA Catalyst
Simply Wall St. âĸ 2026-03-30T01:05:50Z
Insight Molecular Diagnostics Inc. Q4 2025 Earnings Call Summary
Moby âĸ 2026-03-27T12:30:00Z
Insight Molecular Diagnostics: Q4 Earnings Snapshot
Associated Press Finance âĸ 2026-03-26T20:27:56ZHow Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones
Simply Wall St. âĸ 2026-03-14T04:23:04Z
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Funding And GraftAssureDx Catalyst
Simply Wall St. âĸ 2026-02-27T20:09:35Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $424,000 | $1,141,000 | $1,090,000 | $976,000 |
| Cost Of Revenue | $1,757,000 | $1,141,000 | $1,090,000 | $976,000 |
| Total Revenue | $4,055,000 | $1,881,000 | $1,503,000 | $958,000 |
| Operating Revenue | $4,055,000 | $1,881,000 | $1,503,000 | $958,000 |
| Expenses | ||||
| Interest Expense | $109,000 | $84,000 | $52,000 | $83,000 |
| Total Expenses | $34,633,000 | $25,128,000 | $23,920,000 | $29,810,000 |
| Other Income Expense | $-19,535,000 | $-37,332,000 | $-2,386,000 | $10,323,000 |
| Other Non Operating Income Expenses | $1,011,000 | $462,000 | $394,000 | $-61,000 |
| Net Non Operating Interest Income Expense | $-109,000 | $-84,000 | $-52,000 | $-83,000 |
| Interest Expense Non Operating | $109,000 | $84,000 | $52,000 | $83,000 |
| Operating Expense | $32,876,000 | $23,987,000 | $22,830,000 | $28,834,000 |
| Selling And Marketing Expense | $1,213,000 | $641,000 | $307,000 | $17,000 |
| General And Administrative Expense | $14,899,000 | $13,144,000 | $12,978,000 | $21,516,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-50,222,000 | $-60,663,000 | $-24,855,000 | $-18,612,000 |
| Net Interest Income | $-109,000 | $-84,000 | $-52,000 | $-83,000 |
| Normalized Income | $-29,676,000 | $-22,869,000 | $-22,075,000 | $-28,996,000 |
| Net Income From Continuing And Discontinued Operation | $-50,222,000 | $-60,663,000 | $-27,781,000 | $-72,902,000 |
| Total Operating Income As Reported | $-51,124,000 | $-61,041,000 | $-25,136,000 | $-17,997,000 |
| Net Income Common Stockholders | $-50,222,000 | $-60,926,000 | $-28,723,000 | $-73,422,000 |
| Net Income | $-50,222,000 | $-60,663,000 | $-27,781,000 | $-72,902,000 |
| Net Income Including Noncontrolling Interests | $-50,222,000 | $-60,663,000 | $-27,781,000 | $-72,902,000 |
| Net Income Continuous Operations | $-50,222,000 | $-60,663,000 | $-24,855,000 | $-18,612,000 |
| Pretax Income | $-50,222,000 | $-60,663,000 | $-24,855,000 | $-18,612,000 |
| Special Income Charges | $-20,546,000 | $-37,794,000 | $-2,719,000 | $10,855,000 |
| Operating Income | $-30,578,000 | $-23,247,000 | $-22,417,000 | $-28,852,000 |
| Depreciation Amortization Depletion Income Statement | $864,000 | $363,000 | $251,000 | - |
| Depreciation And Amortization In Income Statement | $864,000 | $363,000 | $251,000 | - |
| Gross Profit | $2,298,000 | $740,000 | $413,000 | $-18,000 |
| Net Income Discontinuous Operations | - | $0 | $-2,926,000 | $-54,290,000 |
| Earnings From Equity Interest | - | - | - | $0 |
| Per Share | ||||
| Diluted EPS | $-1.65 | $-4.66 | $-3.75 | $-20.00 |
| Basic EPS | $-1.65 | $-4.66 | $-3.75 | $-20.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-27,370,000 | $-21,221,000 | $-20,343,000 | $-23,693,000 |
| Total Unusual Items | $-20,546,000 | $-37,794,000 | $-2,780,000 | $10,384,000 |
| Total Unusual Items Excluding Goodwill | $-20,546,000 | $-37,794,000 | $-2,780,000 | $10,384,000 |
| Reconciled Depreciation | $2,197,000 | $1,564,000 | $1,680,000 | $5,220,000 |
| EBITDA (Bullshit earnings) | $-47,916,000 | $-59,015,000 | $-23,123,000 | $-13,309,000 |
| EBIT | $-50,113,000 | $-60,579,000 | $-24,803,000 | $-18,529,000 |
| Diluted Average Shares | $30,476,000 | $13,071,000 | $7,651,000 | $5,540,000 |
| Basic Average Shares | $30,476,000 | $13,071,000 | $7,651,000 | $5,540,000 |
| Diluted NI Availto Com Stockholders | $-50,222,000 | $-60,926,000 | $-28,723,000 | $-73,422,000 |
| Write Off | $0 | $169,000 | $1,283,000 | - |
| Impairment Of Capital Assets | $14,600,000 | $41,900,000 | $6,757,000 | $18,684,000 |
| Restructuring And Mergern Acquisition | $5,946,000 | $-4,275,000 | $-5,321,000 | $-29,539,000 |
| Research And Development | $15,900,000 | $9,839,000 | $9,294,000 | $7,301,000 |
| Selling General And Administration | $16,112,000 | $13,785,000 | $13,285,000 | $21,533,000 |
| Other Gand A | $3,748,000 | $4,007,000 | $3,510,000 | $5,334,000 |
| Insurance And Claims | $1,247,000 | $1,546,000 | $2,637,000 | $2,739,000 |
| Salaries And Wages | $9,904,000 | $7,591,000 | $6,831,000 | $13,443,000 |
| Preferred Stock Dividends | - | $263,000 | $942,000 | $520,000 |
| Gain On Sale Of Ppe | - | - | $-1,283,000 | $0 |
| Gain On Sale Of Security | - | - | $-61,000 | $-471,000 |
| Otherunder Preferred Stock Dividend | - | - | - | $520,000 |
| Tax Provision | - | - | - | $0 |
| Other Special Charges | - | - | - | - |
Fetched: 2026-06-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-31,464,000 | $-26,881,000 | $-36,127,000 | $-27,341,000 |
| Total Assets | $25,756,000 | $35,081,000 | $74,892,000 | $100,091,000 |
| Total Non Current Assets | $10,450,000 | $23,322,000 | $64,194,000 | $74,555,000 |
| Other Non Current Assets | $1,200,000 | $2,391,000 | $2,163,000 | $2,071,000 |
| Goodwill And Other Intangible Assets | $0 | $14,607,000 | $56,595,000 | $61,633,000 |
| Current Assets | $15,306,000 | $11,759,000 | $10,698,000 | $25,536,000 |
| Other Current Assets | $1,420,000 | $821,000 | $643,000 | $977,000 |
| Current Deferred Assets | $0 | $279,000 | $0 | - |
| Restricted Cash | $729,000 | $0 | - | - |
| Inventory | $446,000 | $410,000 | $0 | - |
| Receivables | $1,128,000 | $1,613,000 | $484,000 | $2,012,000 |
| Accounts Receivable | $1,128,000 | $1,613,000 | $484,000 | $2,012,000 |
| Allowance For Doubtful Accounts Receivable | $-11,000 | $-16,000 | $-5,000 | $-154,000 |
| Gross Accounts Receivable | $1,139,000 | $1,629,000 | $489,000 | $2,166,000 |
| Cash Cash Equivalents And Short Term Investments | $11,583,000 | $8,636,000 | $9,432,000 | $20,426,000 |
| Cash And Cash Equivalents | $11,583,000 | $8,636,000 | $9,432,000 | $19,993,000 |
| Other Intangible Assets | - | $14,607,000 | $56,595,000 | $61,633,000 |
| Assets Held For Sale Current | - | $0 | $139,000 | $2,121,000 |
| Prepaid Assets | - | - | - | - |
| Notes Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $3,497,000 | $3,664,000 | $2,869,000 | $3,544,000 |
| Long Term Debt And Capital Lease Obligation | $1,690,000 | $2,369,000 | $2,204,000 | $2,729,000 |
| Current Debt And Capital Lease Obligation | $1,807,000 | $1,295,000 | $665,000 | $815,000 |
| Current Debt | - | - | - | - |
| Other Current Borrowings | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $57,220,000 | $47,355,000 | $54,424,000 | $65,799,000 |
| Total Non Current Liabilities Net Minority Interest | $45,145,000 | $40,080,000 | $47,230,000 | $53,693,000 |
| Other Non Current Liabilities | $43,455,000 | $37,711,000 | $39,900,000 | $45,662,000 |
| Current Liabilities | $12,075,000 | $7,275,000 | $7,194,000 | $12,106,000 |
| Payables And Accrued Expenses | $7,379,000 | $3,813,000 | $2,521,000 | $5,201,000 |
| Payables | $5,324,000 | $2,279,000 | $953,000 | $1,253,000 |
| Accounts Payable | $2,544,000 | $1,641,000 | $953,000 | $1,253,000 |
| Other Current Liabilities | - | - | $45,000 | $2,005,000 |
| Equity | ||||
| Common Stock Equity | $-31,464,000 | $-12,274,000 | $20,468,000 | $34,292,000 |
| Total Equity Gross Minority Interest | $-31,464,000 | $-12,274,000 | $20,468,000 | $34,292,000 |
| Stockholders Equity | $-31,464,000 | $-12,274,000 | $20,468,000 | $34,292,000 |
| Gains Losses Not Affecting Retained Earnings | $86,000 | $21,000 | $49,000 | $39,000 |
| Other Equity Adjustments | $86,000 | $21,000 | $49,000 | $39,000 |
| Retained Earnings | $-400,761,000 | $-350,539,000 | $-289,876,000 | $-260,676,000 |
| Preferred Securities Outside Stock Equity | $0 | $0 | $5,126,000 | $5,302,000 |
| Long Term Equity Investment | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $28,682,844 | $17,452,824 | $8,260,762 | $5,932,200 |
| Share Issued | $28,682,844 | $17,452,824 | $8,260,762 | $5,932,200 |
| Tangible Book Value | $-31,464,000 | $-26,881,000 | $-36,127,000 | $-27,341,000 |
| Invested Capital | $-31,464,000 | $-12,274,000 | $20,468,000 | $34,292,000 |
| Working Capital | $3,231,000 | $4,484,000 | $3,504,000 | $13,430,000 |
| Capital Lease Obligations | $3,497,000 | $3,664,000 | $2,869,000 | $3,544,000 |
| Total Capitalization | $-31,464,000 | $-12,274,000 | $20,468,000 | $34,292,000 |
| Capital Stock | $369,211,000 | $338,244,000 | $310,295,000 | $294,929,000 |
| Common Stock | $369,211,000 | $338,244,000 | $310,295,000 | $294,929,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,690,000 | $2,369,000 | $2,204,000 | $2,729,000 |
| Current Capital Lease Obligation | $1,807,000 | $1,295,000 | $665,000 | $815,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,889,000 | $2,167,000 | $3,963,000 | $4,085,000 |
| Current Accrued Expenses | $2,055,000 | $1,534,000 | $1,568,000 | $3,948,000 |
| Dueto Related Parties Current | $2,780,000 | $638,000 | - | - |
| Net PPE | $9,250,000 | $6,324,000 | $5,436,000 | $10,851,000 |
| Accumulated Depreciation | $-9,654,000 | $-7,705,000 | $-6,235,000 | - |
| Gross PPE | $18,904,000 | $14,029,000 | $11,671,000 | $10,851,000 |
| Construction In Progress | $765,000 | $340,000 | $726,000 | - |
| Other Properties | $5,623,000 | $5,323,000 | $4,036,000 | $2,179,000 |
| Machinery Furniture Equipment | $12,516,000 | $8,366,000 | $6,909,000 | $8,672,000 |
| Finished Goods | - | $203,000 | - | - |
| Raw Materials | - | $207,000 | - | - |
| Treasury Shares Number | - | - | $0 | - |
| Other Short Term Investments | - | - | $0 | $433,000 |
| Line Of Credit | - | - | - | $0 |
| Goodwill | - | - | - | $0 |
| Investments And Advances | - | - | - | - |
Fetched: 2026-06-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-25,369,000 | $-21,205,000 | $-23,606,000 | $-49,908,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-22,184,000 | $-20,689,000 | $-23,325,000 | $-45,568,000 |
| Cash Flow From Continuing Operating Activities | $-22,184,000 | $-20,689,000 | $-23,325,000 | $-45,568,000 |
| Operating Gains Losses | $185,000 | $-4,000 | $61,000 | $471,000 |
| Investing Activities | ||||
| Capital Expenditure | $-3,185,000 | $-516,000 | $-281,000 | $-4,340,000 |
| Investing Cash Flow | $-3,185,000 | $-512,000 | $-932,000 | $-4,340,000 |
| Cash Flow From Continuing Investing Activities | $-3,185,000 | $-512,000 | $440,000 | $-4,340,000 |
| Cash From Discontinued Investing Activities | - | $0 | $-1,372,000 | $0 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $-5,389,000 | $-1,118,000 | $0 |
| Issuance Of Capital Stock | $29,143,000 | $27,814,000 | $13,848,000 | $37,718,000 |
| Financing Cash Flow | $28,072,000 | $20,429,000 | $12,186,000 | $35,806,000 |
| Cash Flow From Continuing Financing Activities | $28,072,000 | $20,429,000 | $12,186,000 | $35,806,000 |
| Net Other Financing Charges | $-559,000 | $-1,795,000 | $-427,000 | $-483,000 |
| Net Preferred Stock Issuance | $0 | $-5,389,000 | $-1,118,000 | $4,875,000 |
| Net Common Stock Issuance | $29,143,000 | $27,814,000 | $13,848,000 | $32,843,000 |
| Common Stock Issuance | $29,143,000 | $27,814,000 | $13,848,000 | $32,843,000 |
| Preferred Stock Issuance | - | - | $0 | $4,875,000 |
| Other | ||||
| Repayment Of Debt | $-512,000 | $-201,000 | $-117,000 | $-1,429,000 |
| Interest Paid Supplemental Data | $91,000 | $42,000 | $7,000 | $24,000 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $12,919,000 | $10,336,000 | $11,132,000 | $23,203,000 |
| Beginning Cash Position | $10,336,000 | $11,132,000 | $23,203,000 | $37,305,000 |
| Effect Of Exchange Rate Changes | $-120,000 | $-24,000 | - | - |
| Changes In Cash | $2,703,000 | $-772,000 | $-12,071,000 | $-14,102,000 |
| Preferred Stock Payments | $0 | $-5,389,000 | $-1,118,000 | $0 |
| Net Issuance Payments Of Debt | $-512,000 | $-201,000 | $-117,000 | $-1,429,000 |
| Net Long Term Debt Issuance | $-512,000 | $-201,000 | $-117,000 | $-104,000 |
| Long Term Debt Payments | $-512,000 | $-201,000 | $-117,000 | $-104,000 |
| Net PPE Purchase And Sale | $-3,185,000 | $-512,000 | $73,000 | $-4,340,000 |
| Sale Of PPE | $0 | $4,000 | $354,000 | $0 |
| Purchase Of PPE | $-3,185,000 | $-516,000 | $-281,000 | $-4,340,000 |
| Change In Working Capital | $2,727,000 | $-1,293,000 | $-3,971,000 | $-1,942,000 |
| Change In Other Working Capital | $-142,000 | $-291,000 | $-107,000 | $-116,000 |
| Change In Payables And Accrued Expense | $2,646,000 | $967,000 | $-4,757,000 | $-1,020,000 |
| Change In Prepaid Assets | $-226,000 | $-430,000 | $784,000 | $-231,000 |
| Change In Inventory | $-36,000 | $-410,000 | $0 | - |
| Change In Receivables | $485,000 | $-1,129,000 | $109,000 | $-575,000 |
| Changes In Account Receivables | $485,000 | $-1,129,000 | $109,000 | $-575,000 |
| Other Non Cash Items | $5,946,000 | $-4,275,000 | $-4,241,000 | $-31,007,000 |
| Stock Based Compensation | $2,383,000 | $1,913,000 | $2,887,000 | $10,042,000 |
| Asset Impairment Charge | $14,600,000 | $42,069,000 | $8,040,000 | $44,550,000 |
| Depreciation Amortization Depletion | $2,197,000 | $1,564,000 | $1,680,000 | $5,220,000 |
| Depreciation And Amortization | $2,197,000 | $1,564,000 | $1,680,000 | $5,220,000 |
| Amortization Cash Flow | $7,000 | $88,000 | $88,000 | $3,692,000 |
| Amortization Of Intangibles | $7,000 | $88,000 | $88,000 | $3,692,000 |
| Depreciation | $2,190,000 | $1,476,000 | $1,592,000 | $1,528,000 |
| Net Foreign Currency Exchange Gain Loss | $185,000 | $-4,000 | - | - |
| Net Income From Continuing Operations | $-50,222,000 | $-60,663,000 | $-27,781,000 | $-72,902,000 |
| Net Investment Purchase And Sale | - | $0 | $367,000 | $0 |
| Sale Of Investment | - | $0 | $367,000 | $0 |
| Net Short Term Debt Issuance | - | - | $0 | $-1,325,000 |
| Short Term Debt Payments | - | - | $0 | $-1,325,000 |
| Change In Accrued Expense | - | - | $0 | $-1,317,000 |
| Change In Payable | - | - | $-4,757,000 | $297,000 |
| Change In Account Payable | - | - | $-4,757,000 | $297,000 |
| Gain Loss On Investment Securities | - | - | $61,000 | $471,000 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Common Stock Payments | - | - | - | $0 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Purchase Of Business | - | - | - | $0 |
| Change In Other Current Liabilities | - | - | - | $-116,000 |
| Unrealized Gain Loss On Investment Securities | - | - | - | $471,000 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Earnings Losses From Equity Investments | - | - | - | $0 |
| Issuance Of Debt | - | - | - | - |
| Long Term Debt Issuance | - | - | - | - |
| Pension And Employee Benefit Expense | - | - | - | - |
Fetched: 2026-06-23